Purpose Our objective was to develop a system to simultaneously and quantitatively measure the expression levels of the insulin-like growth factor (IGF) family proteins in numerous samples and to apply this approach to profile the IGF family proteins levels in cancer and adjacent tissues from patients with hepatocellular carcinoma (HCC). Experimental Design Antibodies against ten IGF family proteins (IGF-1, IGF-1R, IGF-2, IGF-2R, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-6, and Insulin) were immobilized on the surface of a glass slide in an array format to create an IGF signaling antibody array. Tissue lysates prepared from patient's liver cancer tissues and adjacent tissues were then applied to the arrays. The proteins captured by antibodies on the arrays were then incubated with a cocktail of biotinylated detection antibodies and visualized with a fluorescence detection system. By comparison with standard protein amount, the exact protein concentrations in the samples can be determined. The expression levels of the ten IGF family proteins in 25 pairs of HCC and adjacent tissues were quantitatively measured using this novel antibody array technology. The differential expression levels between cancer tissues and adjacent tissues were statistically analyzed. Results A novel IGF signaling antibody array was developed which allows the researcher to simultaneously detect ten proteins involved in IGF signal pathway with high sensitivity and specificity. Using this approach, we found that the levels of IGF-2R and IGFBP-2 in HCC tissues were higher than those in adjacent tissues. Conclusion Our IGF signaling antibody array which can detect the expression of ten IGF family members with high sensitivity and specificity will undoubtedly prove a powerful tool for drug and biomarker discovery.
References
[1]
Delafontaine P, Song YH, Li Y (2004) Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24: 435–444.
[2]
Lelbach A, Muzes G, Feher J (2005) The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung 92: 97–107.
[3]
Chao W, D'Amore PA (2008) IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 19: 111–120.
[4]
Clemmons DR (2007) Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6: 821–833.
[5]
Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, et al. (2001) In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 142: 1652–1658.
[6]
Muller HL, Oh Y, Lehrnbecher T, Blum WF, Rosenfeld RG (1994) Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 79: 428–434.
[7]
Collett-Solberg PF, Cohen P (2000) Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine 12: 121–136.
[8]
Ricort JM (2004) Insulin-like growth factor binding protein (IGFBP) signalling. Growth Horm IGF Res 14: 277–286.
[9]
Annunziata M, Granata R, Ghigo E (2011) The IGF system. Acta Diabetol 2011 Mar;48 (1) 1–9.
[10]
Chaves J, Saif MW (2011) IGF system in cancer: from bench to clinic. Anticancer Drugs 22 (3) 206–12.
[11]
Rosenzweig SA, Atreya HS (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80 (8) 1115–24.
[12]
Tognon CE, Sorensen PH (2012) Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 16 (1) 33–48.
[13]
Ruan W, Lai M (2010) Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 47 (1) 5–14.
[14]
Huang RP (2004) Cytokine protein arrays. Methods Mol Biol 264: 215–231.
[15]
Huang RP (2003) Cytokine antibody arrays: a promising tool to identify molecular targets for drug discovery. Comb Chem High Throughput Screen 6: 769–775.
[16]
Huang RP (2003) Protein arrays, an excellent tool in biomedical research. Front Biosci 8: d559–576.
[17]
Huang RP (2001) Simultaneous detection of multiple proteins with an array-based enzyme-linked immunosorbent assay (ELISA) and enhanced chemiluminescence (ECL). Clin Chem Lab Med 39: 209–214.
[18]
Engvall E (1977) Quantitative enzyme immunoassay (ELISA) in microbiology. Med Biol 55: 193–200.
Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, et al. (2008) ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 63: 879–884.
[21]
Iakova P, Timchenko L, Timchenko NA (2011) Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol 21: 28–34.
[22]
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118–1127.
Su TS, Liu WY, Han SH, Jansen M, Yang-Fen TL, et al. (1989) Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 49: 1773–1777.
[25]
Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, et al. (1998) Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis 19: 2121–2128.
[26]
Yang DY, Rogler CE (1991) Analysis of insulin-like growth factor II (IGF-II) expression in neoplastic nodules and hepatocellular carcinomas of woodchucks utilizing in situ hybridization and immunocytochemistry. Carcinogenesis 12: 1893–1901.
[27]
Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, et al. (1988) Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48: 6844–6849.
[28]
Ng IO, Lee JM, Srivastava G, Ng M (1998) Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. J Gastroenterol Hepatol 13: 152–157.
[29]
Uchida K, Kondo M, Takeda S, Osada H, Takahashi T, et al. (1997) Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol Carcinog 18: 193–198.
[30]
Boissan M, Beurel E, Wendum D, Rey C, Lecluse Y, et al. (2005) Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 167: 869–877.
[31]
Gong Y, Cui L, Minuk GY (2000) The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol Cell Biochem 207: 101–104.
[32]
Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, et al. (2003) Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 60: 174–180.
[33]
Pavelic K, Bukovic D, Pavelic J (2002) The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 8: 771–780.
[34]
Osipo C, Dorman S, Frankfater A (2001) Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors. Exp Cell Res 264: 388–396.
[35]
Sztefko K, Hodorowicz-Zaniewska D, Popiela T, Richter P (2009) IGF-I, IGF-II, IGFBP2, IGFBP3 and acid-labile subunit (ALS) in colorectal cancer patients before surgery and during one year follow up in relation to age. Adv Med Sci 54: 51–58.
[36]
Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, et al. (2005) Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58: 361–366.
[37]
Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, et al. (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 61: 8601–8610.
[38]
Lin Y, Huang R, Chen LP, Lisoukov H, Lu ZH, Li SY, et al. (2003) Profiling of cytokine expression by biotin-labeled-based protein arrays. Proteomics 3: 1750–1757.
